Which of the following best describes the MOA of Sulfonylureas?

• A. Increase glucose uptake by muscle
• B. Increase insulin release by stimulating pancreatic B-Cells
• C. Decrease insulin resistance
• D. Inhibit hepatic glucose production

Answer: (B)

Sulfonylureas are a class of oral hypoglycemic agents commonly used in the management of type 2 diabetes. Their primary mechanism of action is through stimulating the pancreatic beta cells to release more insulin. This happens by binding to specific receptors on the surface of these cells, which leads to the closure of ATP-sensitive potassium channels. When these channels close, it causes depolarization of the cell membrane, resulting in an influx of calcium ions that prompts the release of insulin stored in the granules of the beta cells.

This action directly contributes to lowering blood glucose levels by increasing the amount of insulin available to facilitate the uptake of glucose by tissues, particularly muscle and fat. However, the fundamental mechanism underlying sulfonylureas is the enhancement of insulin release rather than increasing uptake or decreasing resistance in peripheral tissues.

Understanding this mechanism is critical for grasping how these medications help manage blood sugar levels in diabetic patients and how they can be integrated into a broader treatment plan that may include lifestyle modifications and other medications targeting different pathways, such as insulin sensitivity and hepatic glucose production.